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Abstract
Precursors and preinvasive lesions of the breast include atypical ductal hyperplasia (ADH), ductal
carcinoma in situ (DCIS), and lobular neoplasia (LN). There is a significant debate regarding the
classification, diagnosis, prognosis and management of these lesions. This review article describes
the current theories regarding the pathogenesis and molecular evolution of these lesions. It reviews
the implication of a variety of molecules in the continuum of breast lesions: estrogen receptors (ER-
alpha and ER-beta), c-erb-B2 (Her2/neu), p53, Ki-67, bcl-2, E-cadherin, transforming growth factor-
beta (TGF-beta), p27 (Kip1), p16 (INK4a), p21 (Waf1), vascular endothelial growth factor (VEGF).
With respect to the aforementioned molecules, this article reviews their pathophysiological
importance, and puts the stress on whether they confer additional risk for invasive breast cancer
or not. This knowledge has the potential to be of importance in the therapeutic decisions
presenting in the common clinical practice.
Background
Precursors and preinvasive lesions of the breast, which
include atypical ductal hyperplasia (ADH), ductal carci-
noma in situ (DCIS), and lobular neoplasia (LN), repre-
sent an heterogeneous entity with a lot of problems
associated with the definition, classification, diagnosis
and management of patients [1-5]. The diagnosis of these
lesions represents a clinical dilemma for the patient and
the physicians [2,3,5]. Following a diagnosis of atypical
hyperplasia or DCIS, a patient is immediately considered
at high risk for future development of invasive breast car-
cinoma, although this progression will only occur in a
portion of patients [6,7]. Uncertainties in the prognosis
have given rise to a debate surrounding the appropriate
treatment, involving a wide range of treatment
approaches from observation to mastectomy. This has
resulted in diverse and confusing clinical recommenda-
tions, distressing to both patients and clinicians [3,8,9].
The use of molecular markers in the common clinical
practice seems promising for the diagnosis and prognosti-
cation. Molecular markers nowadays seem to have the
potential to improve our ability to care for patients with,
or at risk for, breast cancer.
The aim of this review article is to describe the current the-
ories regarding the pathogenesis and molecular evolution
of preinvasive breast lesions. With respect to the mole-
cules implicated, this article focuses especially on whether
they confer additional risk for invasive breast cancer or
Published: 31 May 2007
World Journal of Surgical Oncology 2007, 5:57 doi:10.1186/1477-7819-5-57
Received: 20 April 2007
Accepted: 31 May 2007
This article is available from: http://www.wjso.com/content/5/1/57
© 2007 Zagouri et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2007, 5:57 http://www.wjso.com/content/5/1/57
Page 2 of 11
(page number not for citation purposes)
not. The evaluation of molecular markers is performed
under the light of their potential usefulness in treatment
decisions presenting in the common clinical practice.
Precursors and preinvasive lesions of the breast
ADH represents a proliferative lesion that fulfils some, but
not all the criteria for a diagnosis of low-grade, non-
comedo type DCIS [2,10]. In essence, ADH is usually
small and focal, measuring less than 2 to 3 mm. ADH is a
rare condition, being seen in 4% of symptomatic benign
biopsies [1]. The significance of the diagnosis of ADH lies
in the increased risk of subsequent invasive breast carci-
noma (relative risk RR = 4.4) [10]. When ADH is com-
bined with a positive family history, the relative risk of
invasive cancer reaches 9.7 [11,12]. The major problem
with regard to ADH is the difficulty in achieving accepta-
ble levels of concordance or consistency in diagnosis.
There is significant inter-observer [13] variability in the
diagnosis of ADH. It should also always be born in mind
that proliferation at the edge of a biopsy may represent the
periphery of a more established lesion of DCIS [1].
DCIS is defined as a proliferation of malignant epithelial
cells within the breast parenchymal structures with no evi-
dence of invasion across the basement membrane [1].
Presently, DCIS constitutes 15–20% of screen-detected
malignancies of the breast [14,15], and it is known that
such a diagnosis confers an 8-10-fold elevated risk for the
development of IBC [16]. Studies suggest that up to 50%
of patients with microscopic foci of DCIS develop invasive
carcinoma [1,6,7]. Additionally, it has been shown that
progression to invasion is related to the subtype of DCIS;
comedo disease progresses into invasive carcinoma both
more often and more rapidly than low-grade DCIS [1,17].
LN is characterized by the proliferation of generally small
and often loosely cohesive cells. The term LN refers to the
entire spectrum of atypical epithelial proliferations origi-
nating in the terminal duct-lobular unit (TDLU), with or
without pagetoid involvement of terminal ducts [2,4]. The
designations ALH and LCIS, have been widely used for
varying degrees of the lesions [2,18,19]. LN is a "marker of
increased risk" rather than a true precursor of invasive car-
cinoma. ALH confers a 3-fold elevated risk for the devel-
opment of IBC, while LCIS has a relative risk equal to 7
[2,20]. LN is multicentric in as many as 85% of patients
and bilateral in 30% of women who had undergone bilat-
eral mastectomy [2,4,19,20].
Histological models of the progression to invasive 
carcinoma
Over the past twenty years, a histological model of human
breast cancer evolution was predominant [21,22]. The
multistep model of breast carcinogenesis supports a tran-
sition from normal epithelium to invasive carcinoma via
non-atypical hyperplasia, atypical hyperplasia and in situ
carcinoma [4,23,24]. Confirmatory evidence that precur-
sors and preinvasive lesions are clonal processes arises
from studies showing similar genetic changes in low-
grade DCIS and ADH (Table 1), and identical genetic
abnormalities with synchronous ipsilateral invasive breast
cancer [4,25-34]. These studies were supported by mouse
mammary tumor models [35] and by epidemiological
studies [36] which showed that the risk for breast cancer
increased with the rate of proliferation and atypia in
breast biopsies. The fact that the invasive carcinoma
occurs in the same area as the original indicates a precur-
sor progress [1,39].
On the other hand, the lack of direct evidence for the lin-
ear progression model gave birth to new models. Farabe-
goli et al. [40] proved that DCIS is a possible, but not an
obligate precursor of invasive breast cancer and suggest
that pure DCIS and DCIS associated with IDC may be
genetically distinct. The evolution from DCIS to IDC may
thus follow multiple pathways rather than a linear model.
Leong et al. suggested that in most cases, low-grade DCIS
is associated with low-grade invasive carcinoma and high-
grade DCIS with high-grade invasive carcinoma, i.e., hor-
izontal progression. They postulated that intermediate-
grade DCIS is heterogeneous and it is therefore possible
that this group represents some cases of DCIS that have
progressed from low-grade DCIS as well as cases that may
progress to high-grade DCIS, suggesting that progression
may not be entirely horizontal in intermediate-grade
DCIS [39-43].
Classification
All cases of ADH, LN, and DCIS do not have the same pos-
sibility to progress to invasive carcinoma [1,6,7]. It
became thus obvious that a uniform approach is incor-
rect, and a subclassification arose. However, there is no
specific classification for ADH and LN, while for DCIS the
Van Nuys classification is the most widely accepted
method for risk estimation and has replaced the Holland,
the Bellamy, the Leal and the Lagios classifications [39].
The Van Nuys Prognostic Index (VNPI) combines three
significant predictors of local recurrence: tumor size, mar-
gin width, and pathologic classification (nuclear grade,
comedo-type necrosis). According to the VNPI, DCIS is
classified into three groups with low, intermediate, or
high risk of local recurrence after breast conserving ther-
apy [44].
Molecular markers
It has become apparent that the existing classification sys-
tems of precursors and preinvasive lesions are not ade-
quate. The challenge lies in using available clinical and
pathologic data to estimate the individual relative risk for
invasive breast carcinoma rather than the relative risk ofWorld Journal of Surgical Oncology 2007, 5:57 http://www.wjso.com/content/5/1/57
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each lesion. This could be helpful for the selection of the
most appropriate therapy for each individual patient. In
the following pages, the available data with respect to
important molecules are presented in detail. Table 2 sum-
marizes the main features regarding the presented mole-
cules.
Estrogen receptors (ER)
Estrogens play a central role in the growth and differenti-
ation of normal breast epithelium, stimulating cell prolif-
eration and regulating the expression of other genes,
including the progesterone receptor (PgR) [45-47]. In the
normal pre-menopausal breast, ER(+) cells comprise the
7% of the total epithelial cell population [48]. ER(+) cells
are luminal epithelial cells, evenly distributed, and seem
to secrete factors which paracrinely influence the prolifer-
ation of the adjacent ER(-) cells [48,49]. It should be
noted that ER positivity and proliferation (as depicted by
ki-67 expression, see below) are almost mutually exclu-
sive in normal epithelial breast tissue [49]. ER+ cells
increase with age, reaching a plateau after menopause
[50].
The intensity of ER expression in the normal epithelium is
a risk factor for breast cancer, conferring a 3-fold increase
in risk [51]. More specifically, regarding non-atypical epi-
thelial hyperplasia, ER positivity together with ki-67
expression, seem to make an important distinction
between lesions: the existence of ki-67(+)/ER(+) cells
seems to correlate with progression to more severe lesions
[52]. Alternatively, it has been suggested that an increased
percentage of ER(+) cells in the adjacent normal lobules
seems to be associated with elevated risk for invasive
breast cancer rather than ER-positivity within the lesion
per se [53].
In other benign breast lesions, such as sclerosing adenosis,
radial scars, papillomas, fibroadenomas, and phylloides
tumours, the percentage of ER(+) cells is higher than nor-
mal breast tissue [54]. Similarly, ER-alpha expression has
been proven significantly elevated in the hyperplastic
enlarged lobular unit (HELU), which represents the earli-
est histologically identifiable lesion with premalignant
potential. On the contrary, as far as enlarged lobular units
with columnar alteration (ELUCA) are concerned, an
intriguing result emerged, since more intense ER-alpha
staining has been associated with a lower risk of subse-
quent invasive carcinoma in these lesions [55].
In the context of ADH, LN and DCIS, and contrary to the
normal breast, ER(+) cells are surrounded by contiguous
cells characterized also by ER-positivity [49]. Moreover, in
DCIS, the above explained diptych ER(+)/Ki-67(+) is a
Table 2: Molecular markers and their prognostic value in precursors and preinvasive breast lesions.
Molecular markers Prognostic importance
Estrogen receptor-alpha Aggravating, 3-fold increased risk for IDC (normal breast epithelium)
Estrogen receptor-beta Protective
c-erb-B2 Aggravating -not unanimous results with respect to RR
p53 disruption Aggravating – conflicting results regarding the RR of its expression in 
benign lesions
Ki-67 Aggravating – no specific estimation of RR
Bcl-2 Aggravating – no specific estimation of RR
VEGF Aggravating
E-cadherin disruption Aggravating
TGF- beta Ambiguous – loss of TGF-beta-RII is aggravating
p16 disruption Controversial findings
p21 (Waf1) Controversial findings
p27 disruption Aggravating/scarcity of data
14-3-3 sigma hypermethylation Aggravating
Table 1: Genetic predisposition in ADH, LN, DCIS.
Genetic predisposition
Losses Gains
ADH: 1q, 2p, 6q, 9p, 11p, 11q, 13q, 14q, 16q, 17p, 17q, Xq Unknown
ALH: 11q, 16p, 16q, 17p, 22q 6q
DCIS: 1p, 7q, 2p, 2q, 3p, 3q, 4p, 6p, 6q, 7p, 7q, 8p, 8q, 9p, 11p, 11q, 12p, 13q, 14q, 15q, 16p, 16q, 17p, 17q, 18q, 21q 1q, 3q, 6q, 6p, 8q, 17q, 20q, Xq
LCIS: 11q, 13q, 16p, 16q, 17p, 17q, 22q 6qWorld Journal of Surgical Oncology 2007, 5:57 http://www.wjso.com/content/5/1/57
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hallmark [54]. In general, non-comedo carcinomas
exhibit more frequently ER positivity [56,57].
In parallel, the less studied ER-beta, seems also to be of
importance and to exhibit an inverse pattern to that of ER-
alpha, declining during the progression from normal
breast tissue to ADH, DCIS, and IDC [58,59]. Of notice,
according to a recent article, a high ratio ER-alpha/ER-beta
in non-atypical epithelial hyperplasia seems to predict
progression to carcinoma [60]. Finally, for the optimal
envisagement of the ER network, it should be kept in
mind that important regulators exist, such as hsp-27 [61]
or AIB1 [62], exhibiting more intense expression in breast
cancer.
Progesterone receptors (PR)
Similarly to estrogen receptors, progesterone receptors
(PR) have been found elevated very early in premalignant
breast lesions, at the hyperplastic enlarged lobular unit
(HELU) [63]. On the other hand, a decreasing trend for
PR expression has been documented along with progres-
sion to malignancy [64]. In DCIS, PR positivity is associ-
ated with ER positivity and lack of comedo necrosis [65-
67]. Concerning PR positivity, studies are contradictory
with respect to tumor grade [65,66,68,69] and recurrence
rate [[70-72], reviewed in ([72])]. In IDC, progesterone
receptors have been associated with histological grade,
but not with lymph node involvement, tumor size, or
prognosis of the patients [64]. With respect to lobular
neoplasia, there is scarcity of data; PR seem however to be
expressed in the majority of cases [74,75].
More interestingly however, it is the ratio progesterone
receptor A (PRA)/progesterone receptor B (PRB) which
seems to play a central role. In normal breast tissue and
non-atypical hyperplasia, receptors are homogenously
coexpressed, but early during progression, one receptor
(especially PRA in advanced lesions) predominates at a
heterogeneous manner [76]. Indeed, the physiological
role of PRA predominance has been supported by in vitro
studies, demonstrating its modulating effects on cell mor-
phology and adhesion [77,78]. Of notice, in the normal
tissue of BRCA mutation carriers, PRB isoform is strikingly
absent [79].
C-erbB-2 (Her-2/neu)
HER-2/neu, a gene located on 17q, encodes for c-erbB-2
oncoprotein, a tyrosine kinase receptor. Alterations of c-
erbB2 (HER-2/neu) are suggested to be an important
event in malignant transformation [80-82]. According to
a variety of studies, c-erbB-2 has not been found overex-
pressed at the protein level in benign proliferative breast
disease or ADH [83-86]. However, amplification of Her-2/
Neu has been documented with the use of FISH in ADH,
supporting the notion that the degree of HER-2/neu
amplification increases with progression to carcinoma
[87]. Accordingly, patients with benign breast lesions
showing low levels of amplification of the HER-2 gene
have a two-fold increased risk of breast cancer [88]; how-
ever, according to another study, c-erbB-2 overexpression
in benign lesions was not a significant risk factor [89].
With respect to lobular neoplasia, one fourth of LCIS cases
have been found positive for c-erbB-2, irrespectively of the
coexistence of an invasive component [90]. Occasional
positivity has been found also in pleomorphic lobular
(ductal-lobular carcinomas in situ [91].
As far as the role of c-erbB-2 in DCIS is concerned, C-erbB-
2 immunoreactivity has been primarily associated with
DCIS of higher grade, in the absence [63] or presence [92]
of IDC, and with comedo type [93]. Interestingly, given
the association of higher grade with c-erb-B2 amplifica-
tion, the latter has been regarded as an independent prog-
nostic factor [94]. Allred et al [95] documented that the
percentage of c-erb-B2 immunoreactivity is significantly
higher in DCIS than IDC: one of the possible explanations
the authors gave was that c-erb-B2 may be more impor-
tant for the initiation than the progression of breast can-
cer, or that c-erb-B2 may be downregulated during the
progression of breast cancer.
p53
P53 is a tumour suppressor gene located on 17p. p53 pro-
tein mediates its tumor suppressor functions via the tran-
scriptional regulation or repression of a variety of genes
[96-98] and is an important component of breast cancer
pathophysiology [99]. Regarding the role of p53 as a risk
factor in benign breast lesions, there is controversy of
data: the immunohistochemical detection of p53 in
benign breast lesions has been associated with elevated
cancer risk [89], although there are studies with conflict-
ing results [100].
Considering the various types of lesions in the continuum
between benign lesions and breast cancer, various studies
have assessed the role of p53. In epithelial hyperplasia
without atypia, p53 mutations have not been detected
[101]. In ADH, the presence and role of p53 mutations is
still an open field: p53 mutations were initially not docu-
mented [102]; then, studies pointing to p53 mutations
appeared [103], and, more recently, the presence of
mutated p53 in ADH has been demonstrated with the use
of laser capture microdissection microscope, single-
stranded conformational polymorphism (SSCP) and
sequencing [104]. Regarding LN, there is scarcity of data:
in two studies, no p53 immunoreactivity was demon-
strated in LN lesions [105,106], whereas a more recent
one on LCIS reported p53 immunoreactivity in one fifth
of cases [90].World Journal of Surgical Oncology 2007, 5:57 http://www.wjso.com/content/5/1/57
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p53 mutations/accumulation are present in a significant
percentage of DCIS [107-111], especially in the comedo
type [112]. However, the clinical significance of p53 accu-
mulation remains still elusive; although it has been found
to influence the proliferation rate [113], a recent study
showed that it does not affect the proliferation rate of the
DCIS lesion per se [107]. Of notice, the coexistence of
DCIS with IDC is not associated with a different degree of
p53 immunostaining [114].
Ki-67
Ki-67 is a cell cycle-associated nuclear protein, which is
expressed in all cycle phases, with the exception of G0 and
early G1, and reacts with MIB-1 antibody [115]. Protein
Ki-67 is extensively used as a proliferative index and is
linked with malignancy, even in FNA specimens [116].
Moreover, its intrinsic association with apoptosis (bcl-2
status, see below) and p53 expression (see above) seems
to be of importance in the diagnosis and prognosis of pre-
cursors and preinvasive breast lesions: low Ki-67 expres-
sion/bcl-2 positivity and p53 negativity are a trait of ADH
and, subsequently, well-differentiated carcinomas. On the
contrary, high Ki-67 expression/bcl-2 negativity within
the lobules implicate lesions with a potential of poorly
differentiated carcinoma [117]. As mentioned above, also
in the context of non-atypical hyperplasia, high Ki-67 and
ER-alpha expression seem to predict progression to cancer
[51,118].
Interestingly enough, a clinical application of Ki-67
expression intensity seems to emerge. In non-atypical duc-
tal hyperplasia, lesions with high Ki-67 expression can be
clinically detected scintimammographically, since high
(99m)Tc-(V)DMSA uptake seems to be their feature.
According to the authors, this could prove useful in iden-
tifying women with benign but high-risk breast patholo-
gies [119].
Bcl-2
The bcl-2 gene is located on 18q. Bcl-2 protein, belongs to
a family of proteins playing a central role in the regulation
of apoptosis [reviewed in ([120]), [121,122]] and other
pathways [reviewed in ([123])]. With respect to the over-
all role of apoptosis in breast cancer pathogenesis, there
seems to be an intriguing pattern incorporating the prolif-
eration of the lesion. Growth imbalance in favour of pro-
liferation seems crucial in the transition from normal
epithelium to hyperplasia and later, from preinvasive
lesions to IDC. On the contrary, apoptosis becomes more
important at an intermediate stage: in the transition from
hyperplasia to preinvasive lesions, the imbalance is in
favour of apoptosis [124]. Bcl-2 is present in the whole
spectrum of breast lesions: predominantly in benign
lesions, ADH, LN, and well-differentiated DCIS [105,125-
127]. More specifically, there is a gradual increase in the
extent of apoptosis [124,128] and a parallel decrease in
bcl-2 expression in benign/precursors/preinvasive/inva-
sive lesions as they become histologically more aggressive
[128]. Bcl-2 positivity tends to coincide with p53 negativ-
ity in normal breast tissue, non-atypical ductal hyperpla-
sia, ADH, LN and in the majority of the DCIS [105]. The
role of Bcl-2 expression as a risk factor for breast cancer is
described above, together with Ki-67 (see above).
Vascular endothelial growth factor (VEGF) and angiogenesis
VEGF is a potent angiogenic growth factor, commonly
involved in tumor-induced angiogenesis, with a putative
therapeutical significance in the context of breast cancer
[129]. Of notice, VEGF gene polymorphisms have been
associated with modified breast cancer risk in various
populations [130,131].
Viacava et al have thoroughly examined the angiogenesis
in precursor and preinvasive lesions. Increased vasculari-
zation is present in all preinvasive lesions and increases
with lesion severity. In ductal lesions, angiogenesis is
more intense in poorly/intermediately differentiated
intraductal carcinomas than in non-atypical ductal hyper-
plasia and ADH. Similarly, LCIS, showing microvascular
density similar to that of poorly/intermediately differenti-
ated intraductal carcinoma, is more vascularized than
ALH. In the same study, VEGF expression in normal glan-
dular structures was lower than in lesions, with the high-
est levels found in ductal lesions. Interestingly, no
correlation was found between VEGF expression and the
degree of vascularization in that study [132]. On the other
hand, Hieken TJ et al. suggested that VEGF expression may
help predict the biologic aggressiveness of DCIS [133].
Additionally, in the context of DCIS, Vogl et al support
VEGF expression is not regulated by the HER2 pathway
[134].
E-cadherin
E-cadherin, a tumor suppressor gene located on 17q, has
been implicated especially in lobular breast cancer molec-
ular pathogenesis [135]. In clinical practice, immunohis-
tochemistry for E-cadherin is a helpful marker for
differential diagnosis, since most cases of low-grade DCIS
exhibit E-cadherin positivity, whereas LN is almost always
E-cadherin negative [[136], reviewed in ([137]), ([138])].
This implies that E-cadherin disruption is an early event,
prior to progression, in lobular carcinogenesis [139,140];
more specifically, DNA alterations accompanying the loss
of protein expression pertain to LCIS but not to ALH
[140]. As expected according to the above, only few stud-
ies have focused on E-cadherin in ductal lesions. In the
context of DCIS, hypermethylation of E-cadherin 5' CpG
islands has been demonstrated [141], and, at the protein
level, E-cadherin has been linked to better differentiation
[142]. Moreover, mutational analysis of E-cadherin pro-World Journal of Surgical Oncology 2007, 5:57 http://www.wjso.com/content/5/1/57
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vided evidence to support that DCIS is the precursor of
invasive ductal carcinoma in cases where LCIS coexists
[143].
TGF-beta
The transforming growth factor-beta (TGF-β) pathway has
ambivalent importance in the pathogenesis of breast can-
cer [reviewed in ([144])]. Serum TGF-beta levels do not
differ between patients with breast cancer, DCIS and
benign lesions [145]; however, TGF-beta expression
becomes more accentuated in IDC, compared with DCIS
[146]. Surprisingly enough, an interesting study recently
showed that loss of TGF-beta-RII expression in epithelial
cells of hyperplasia without atypia is associated with
increased risk of IDC [147]. No reports exist on ADH and
LN, to our knowledge.
P16 (INK4a)
p16 is an inhibitor of cyclin-dependent kinases 4 and 6
[reviewed in ([148])]. With respect to the role of p16, con-
troversial results exist. According to some authors, aber-
rant methylation of p16 is not demonstrated in benign
conditions, epithelial hyperplasia and intraductal papillo-
mas, but is restricted in cancerous epithelium [149]. On
the contrary, another study showed that IDC demonstrate
hypomethylation of p16 and hyperactivity of the p16
gene (enhanced expression of p16 mRNA), contrary to the
hypermethylated, inactive state in the normal epithelium.
[150]. Independently, Di Vinci et al. distinguish between
p16 hypermethylation and p16 protein overexpression;
the former seems not to be specifically associated with
malignancy and to occur both in benign and malignant
lesions, whereas the latter, together with cytoplasmic
sequestration, is a feature of breast carcinoma. [151]. In
the context of such controversy, no studies exist with
respect to p16 as a risk factor, with the exception of a study
in Poland envisaging p16 as a low penetrance breast can-
cer susceptibility gene [152].
p27 (Kip1)
The p27 gene encodes for an inhibitor of the cyclin – CDK
(cyclin-dependent kinase) active complex, Although
numerous studies exist with respect to the role of p27 in
breast cancer [reviewed in ([153]), ([154]), ([155])], there
is lack of data regarding precursors, preinvasive lesions
and other predisposing conditions. p27 expression has
been documented in DCIS, but its clinicopathological sig-
nificance is still uncertain [156].
P21 (Waf1)
p21 is a cell cycle regulator, implicated in a variety of path-
ways [157]. p21 immunoreactivity has been detected both
in benign and malignant epithelium, and thus its role is
hard to interpret. [126]. Studies focusing especially on
ADH, or LN do not exist. As far as DCIS is concerned, p21
positivity has been independently associated with clinical
recurrence [158]. On the other hand, Oh YL et al. found a
significant correlation between positive p21 immunoreac-
tivity (67.3% of the cases) and well-differentiated histo-
logic grade, non-comedo type, ER-positive and p53-
negativity. According to them, DCIS with p21+/p53- is
likely to be the non-comedo type [156].
14-3-3 sigma
Umbricht et al identified 14-3-3 sigma as a gene whose
expression is lost in breast carcinomas, primarily by meth-
ylation-mediated silencing. Importantly, the hypermeth-
ylation of the locus was absent in hyperplasia without
atypia, but was detectable with increasing frequency as the
breast lesions progressed from atypical hyperplasia to
DCIS, and finally to invasive carcinoma [159]; of notice,
methylated alleles existed in the periductal stromal breast
tissue. Afterwards, a parallel, stepwise reduction at the 14-
3-3 sigma protein level has been documented [160].
Despite the emerging role of 14-3-3 sigma in breast car-
cinogenesis, to date no studies exist assessing its role as a
risk factor for breast cancer development.
Therapeutic decision – perspectives
The evaluation of the molecules whose importance has
been to date elucidated could be adjunctively useful in the
therapeutic decision. A simultaneous presentation of
more than one aggravating factors might detect preinva-
sive lesions at risk of progressing to malignancies and
influence the clinical decisions, such as prophylactic sur-
gery (lumpectomy versus mastectomy for excision of the
diseased ducts before the development of invasive carci-
noma), and chemo-prophylaxis.
For the future of the preinvasive breast lesions' manage-
ment, it is tempting to anticipate the gradual integration
of their molecular profiling in the clinical practice. The
simultaneous evaluation of multiple genes has recently
appeared for the detection of healthy individuals at risk
for breast cancer [161] and will be of special interest also
in the context of ADH or LN. An appropriate combination
of techniques (immunohistochemistry, fluorescent in situ
hybridisation, analysis of LOH, CGH, DNA microarrays
proteomics analysis, etc) might be helpful in this direc-
tion.
Conclusion
The clinician should be aware of recent progresses in
molecular biology, individualising his approach to every
patient based on her own risk factors, tumour markers,
histological profile, psychological and social status, etc.
With respect to the molecular markers presented above,
this article reviews the progress made, but also the existing
controversies which should be further studied. Indeed,World Journal of Surgical Oncology 2007, 5:57 http://www.wjso.com/content/5/1/57
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the existing controversies are particularly significant, and
point to the need for further research.
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